- •The Sclera
- •Preface
- •Contents
- •1.1 Introduction
- •1.2 Development of the Sclera
- •1.2.1.1 First Week
- •1.2.1.2 Second Week
- •1.2.1.3 Third Week
- •1.2.1.4 Fourth Week
- •1.2.1.5 Fifth Week
- •1.2.1.6 Sixth Week
- •1.2.1.7 Seventh Week
- •1.2.1.8 Ninth Week
- •1.2.1.9 Tenth Week
- •1.2.1.10 Thirteenth Week
- •1.2.1.11 Sixteenth Week
- •1.2.1.12 Twenty-Fourth Week
- •1.2.2.1 Collagens
- •1.2.2.2 Proteoglycans
- •1.2.2.3 Glycoproteins
- •1.3 Anatomy
- •1.3.1 Gross and Microscopic Anatomy
- •1.3.1.1 Scleral Foramina
- •Anterior Scleral Foramen
- •Posterior Scleral Foramen
- •1.3.1.2 Layers of the Sclera
- •Episclera
- •Scleral Stroma
- •Lamina Fusca
- •1.3.1.3 Blood Supply and Emissary Canals
- •Vascular Distribution
- •Circulatory Dynamics
- •1.3.1.4 Nerve Supply
- •1.3.2 Ultramicroscopic Anatomy
- •1.3.2.1 Sclera
- •1.3.2.2 Vessels
- •1.4 Biochemistry
- •1.5 Immunohistochemistry
- •1.6 Biomechanics
- •1.7 Molecular Structure
- •1.7.1 Collagen
- •1.7.2 Elastin
- •1.7.3 Proteoglycans
- •1.7.4 Glycoproteins
- •1.7.6 Fibroblast Growth Regulation
- •1.8 Summary
- •References
- •2.1 General Immune Response Considerations
- •2.1.1 Components of the Adaptive Immune Response
- •2.1.1.1 Lymphocytes
- •T Lymphocytes
- •B Lymphocytes
- •Third-Population Lymphocytes or Null Lymphocytes
- •2.1.1.2 Monocytes/Macrophages
- •Phagocytosis
- •Antigen-Presenting Cells
- •2.1.1.3 Polymorphonuclear Granulocytes
- •Neutrophils
- •Eosinophils
- •Basophils/Mast Cells
- •2.1.1.4 Platelets
- •2.1.2 Immunoregulation
- •2.1.2.1 Major Histocompatibility Complex
- •2.1.2.2 Humoral Mechanisms: Antibodies
- •2.1.2.3 Cellular Mechanisms
- •2.1.2.4 Summary
- •2.1.3 Abnormalities of the Immune Response
- •2.1.3.1 Hypersensitivity Reactions
- •Type III Hypersensitivity Reactions
- •Systemic Immune Complex Disease
- •Local Immune Complex Disease (Arthus Reaction)
- •Type IV Hypersensitivity Reactions
- •2.1.3.2 Autoimmunity
- •Mechanisms of Autoimmunity
- •2.2 Connective Tissue and the Immune Response
- •2.2.1 Fibroblast Functions and the Immune Response
- •2.3 The Sclera and the Immune Response: Scleritis
- •2.3.1 Immune Characteristics of the Sclera
- •2.3.2 The Susceptible Host: Immunogenetics
- •2.3.3 Etiology
- •2.3.3.1 Exogenous Agents
- •Viruses
- •Mycobacteria
- •2.3.3.2 Endogenous Substances
- •Glycosaminoglycans
- •Collagen
- •2.3.4 Pathogenesis
- •2.4 Summary
- •References
- •3.1 Investigation of the Illness
- •3.1.1 Major Complaint and History of Present Illness
- •3.1.2 Past History
- •3.1.3 Family History
- •3.1.4 Past and Present Therapy History
- •3.1.5 Review of Systems
- •3.1.6 Systemic Examination
- •3.1.6.1 Head
- •3.1.6.2 Extremities
- •3.1.7 Ocular Examination
- •3.1.7.1 Episcleral and Scleral Examination
- •External Examination of the Eye in Daylight
- •Slit-Lamp Examination
- •Diffuse Illumination
- •Slit-Lamp Illumination
- •Red-Free Illumination
- •3.1.7.2 General Eye Examination
- •Visual Acuity
- •Pupils and Extraocular Muscles
- •Cornea
- •Anterior Uvea
- •Lens
- •Fundus
- •Intraocular Pressure
- •3.2 Diagnostic Tests
- •3.2.1 Blood Tests
- •3.2.1.1 Rheumatoid Factor
- •3.2.1.2 Anticyclic Citrullinated Peptide Antibodies
- •3.2.1.3 Antinuclear Antibodies
- •3.2.1.4 Antineutrophil Cytoplasmic Antibodies
- •3.2.1.5 Circulating Immune Complexes
- •Fluid-Phase Binding Assays
- •C1q-Binding Assay
- •Cell-Binding Assays
- •Raji Cell-Binding Assay
- •3.2.1.6 Complement
- •Quantitation Tests
- •Functional Tests
- •3.2.1.7 HLA Typing
- •3.2.1.8 Antibody Titers Against Infectious Organisms
- •3.2.1.9 Interferon-Gamma Release Assays (IGRAs)
- •3.2.2 Anterior Chamber Polymerase Chain Reaction Testing
- •3.2.3 Smears and Cultures
- •3.2.4 Skin Testing
- •3.2.5 Radiologic Studies
- •3.2.6.1 Anterior Segment Fluorescein Angiography Techniques
- •3.2.6.2 Normal Anterior Segment Fluorescein Angiography
- •Arterial Phase
- •Capillary Phase
- •Venous Phase
- •3.2.7 Anterior Segment Indocyanine Green Angiography
- •3.2.8 Other Imaging Studies
- •3.2.8.1 Ultrasonography
- •A-Scan Ultrasonography
- •B-Scan Ultrasonography
- •High-Frequency Ultrasound Biomicroscopy
- •3.2.8.2 Optical Coherence Tomography
- •3.2.8.3 Computer Tomography Scanning
- •3.2.8.4 Magnetic Resonance Imaging
- •3.3 Biopsy
- •3.3.1 Biopsy for Suspected Systemic Vasculitic Disease
- •3.4 Data Integration: Diagnosis
- •3.5 Therapeutic Plan
- •3.6 Summary
- •References
- •4.1 Episcleritis
- •4.1.1 Introduction
- •4.1.2 Patient Characteristics
- •4.1.3 Clinical Manifestations
- •4.1.4.1 Simple Episcleritis
- •4.1.4.2 Nodular Episcleritis
- •4.1.5 Associated Diseases
- •4.1.6 Precipitating Factors
- •4.2 Scleritis
- •4.2.1 Introduction
- •4.2.2 Patient Characteristics
- •4.2.3 Clinical Manifestations
- •4.2.4.1 Diffuse Anterior Scleritis
- •4.2.4.2 Nodular Anterior Scleritis
- •Differential Diagnosis
- •Paralimbic Scleromalacia
- •Senile Scleral Hyaline Plaques
- •4.2.4.5 Posterior Scleritis
- •Symptoms and Signs
- •Fundus Findings
- •Choroidal Folds
- •Subretinal Mass
- •Disk Edema and Macular Edema
- •Annular Ciliochoroidal Detachment and Serous Retinal Detachment
- •Associated Diseases
- •Complications
- •Ancillary Tests
- •Ultrasonography
- •Computerized Tomography (CT) Scanning
- •Fluorescein Angiography
- •Differential Diagnosis
- •Proptosis, Chemosis, Lid Swelling, and Limitation of Ocular Movements
- •Subretinal Mass
- •Choroidal Folds
- •Annular Ciliochoroidal Detachment and/or Serous Retinal Detachment
- •Disk and Macular Edema
- •4.2.5 Associated Diseases
- •4.2.6 Complications of Scleritis
- •4.2.6.1 Keratopathy
- •Peripheral Corneal Thinning
- •Stromal Keratitis
- •Peripheral Ulcerative Keratitis
- •4.2.6.2 Uveitis
- •4.2.6.3 Glaucoma
- •Angle-Closure Glaucoma
- •Open-Angle Glaucoma
- •Neovascular Glaucoma
- •4.2.6.4 Cataract
- •4.3 Summary
- •References
- •5: Pathology in Scleritis
- •5.1.3 Fibrinoid Necrosis
- •5.2.1 Pathology of Episcleritis
- •5.2.2 Pathology of Scleritis
- •5.2.2.1 Noninfectious Scleritis
- •Sclera
- •Cells
- •Extracellular Matrix
- •Vessels
- •Episclera
- •Conjunctiva
- •Iris, Ciliary Body, and Choroid
- •Cornea
- •Other Ocular Structures
- •Polyarteritis Nodosa
- •Allergic Granulomatous Angiitis (Churg–Strauss Syndrome)
- •Granulomatosis with Polyangiitis (Wegener)
- •Connective Tissue Diseases
- •Clinicopathological Correlates in Infectious Scleritis
- •Systemic Infections
- •Local Infections
- •5.3 Biopsy
- •5.3.1 Noninfectious Necrotizing Scleritis
- •5.3.2 Noninfectious Recurrent Diffuse or Nodular (Nonnecrotizing) Scleritis
- •5.3.3 Infectious Scleritis (Diffuse, Nodular, or Necrotizing Scleritis)
- •5.3.4 Biopsy Technique
- •5.4 Summary
- •References
- •6: Noninfectious Scleritis
- •6.1.1 Adult Rheumatoid Arthritis
- •6.1.1.1 Epidemiology
- •Signs and Symptoms of Joint Involvement
- •Extraarticular Systemic Manifestations
- •6.1.1.2 Systemic Manifestations
- •Onset
- •Tegument
- •Vessels
- •Lung
- •Heart
- •Nervous System
- •Lymph Nodes
- •Larynx
- •Felty’s Syndrome
- •Amyloidosis
- •Miscellaneous
- •6.1.1.3 Ocular Manifestations
- •Keratoconjunctivitis Sicca
- •Scleritis
- •Keratitis
- •Anterior Uveitis
- •Glaucoma
- •Cataract
- •Retinal, Choroidal, and Optic Nerve Changes
- •Motility Disturbances
- •Episcleritis
- •6.1.1.4 Laboratory Findings
- •Rheumatoid Factor
- •Antibodies to Cyclic Citrullinated Polypeptides
- •Complete Blood Count
- •Acute-Phase Reactants
- •Synovial Fluid Analysis
- •Circulating Immune Complexes
- •Antinuclear Antibodies
- •Complement
- •Cryoglobulins
- •Radiographic Evaluation
- •Diagnosis
- •6.1.2 Systemic Lupus Erythematosus
- •6.1.2.1 Epidemiology
- •6.1.2.2 Systemic Manifestations
- •Musculoskeletal
- •Tegument
- •Vessels
- •Kidney
- •Hearth
- •Nervous System
- •Lung
- •Miscellaneous
- •6.1.2.3 Ocular Involvement
- •Scleritis
- •Episcleritis
- •Other Ocular Findings
- •6.1.2.4 Laboratory Findings
- •6.1.2.5 Diagnosis
- •6.1.3 Ankylosing Spondylitis
- •6.1.3.1 Epidemiology
- •6.1.3.2 Systemic Manifestations
- •Articular Involvement
- •Extraarticular Systemic Manifestations
- •6.1.3.3 Ocular Manifestations
- •Anterior Uveitis
- •Scleritis
- •Episcleritis
- •6.1.3.5 Diagnosis
- •6.1.4 Reactive Arthritis (Reiter)
- •6.1.4.1 Epidemiology
- •6.1.4.2 Systemic Manifestations
- •Articular Involvement
- •Extraarticular Systemic Manifestations
- •6.1.4.3 Ocular Manifestations
- •Conjunctivitis
- •Anterior Uveitis
- •Scleritis
- •Episcleritis
- •Other Ocular Findings
- •6.1.4.4 Laboratory and Radiographic Findings
- •6.1.4.5 Diagnosis
- •6.1.5 Psoriatic Arthritis
- •6.1.5.1 Epidemiology
- •6.1.5.2 Systemic Manifestations
- •Skin and Articular Involvement
- •6.1.5.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.5.4 Laboratory and Radiographic Findings
- •6.1.5.5 Diagnosis
- •6.1.6.1 Epidemiology
- •6.1.6.2 Systemic Manifestations
- •Gastrointestinal and Articular Manifestations
- •6.1.6.3 Ocular Manifestations
- •Anterior Uveitis
- •Scleritis
- •Episcleritis
- •Keratitis
- •6.1.6.4 Laboratory and Joint Radiologic Findings
- •6.1.6.5 Diagnosis
- •6.1.7 Relapsing Polychondritis
- •6.1.7.1 Epidemiology
- •6.1.7.2 Systemic Manifestations
- •6.1.7.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.7.4 Laboratory Findings
- •6.1.7.5 Diagnosis
- •6.1.8 Polyarteritis Nodosa
- •6.1.8.1 Epidemiology
- •6.1.8.2 Systemic Manifestations
- •6.1.8.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.8.4 Laboratory and Angiographic Findings
- •6.1.8.5 Diagnosis
- •6.1.9.1 Epidemiology
- •6.1.9.2 Systemic Manifestations
- •6.1.9.3 Ocular Manifestations
- •6.1.9.4 Laboratory Findings
- •6.1.9.5 Diagnosis
- •6.1.10 Granulomatosis with Polyangiitis (Wegener)
- •6.1.10.1 Epidemiology
- •6.1.10.2 Clinical Manifestations
- •6.1.10.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.10.4 Laboratory Findings
- •6.1.10.5 Diagnosis
- •6.1.11 Adamantiades–Behçet’s Disease
- •6.1.11.1 Epidemiology
- •6.1.11.2 Systemic Manifestations
- •6.1.11.3 Ocular Manifestations
- •Scleritis
- •Episcleritis
- •6.1.11.4 Laboratory Findings
- •6.1.11.5 Diagnosis
- •6.1.12 Giant-Cell Arteritis
- •6.1.12.1 Epidemiology
- •6.1.12.2 Systemic Manifestations
- •6.1.12.3 Ocular Manifestations
- •Scleritis
- •6.1.12.4 Laboratory Findings
- •6.1.12.5 Diagnosis
- •6.1.13 Cogan’s Syndrome
- •6.1.13.1 Clinical Manifestations
- •Scleritis
- •Episcleritis
- •6.1.13.2 Laboratory Findings
- •6.2.1 Rosacea
- •6.3.1 Gout
- •6.5 Chemical Injury-Associated Scleritis
- •6.6 Summary
- •References
- •7: Infectious Scleritis
- •7.1 Bacterial Scleritis
- •7.1.1.1 Pathogenesis
- •7.1.1.2 Organisms
- •7.1.1.3 Management
- •7.1.1.4 Therapy
- •7.1.1.5 Prognosis
- •7.1.1.6 Our Experience
- •7.1.2 Mycobacterial Scleritis
- •7.1.2.1 Atypical Mycobacterial Disease
- •7.1.2.2 Tuberculosis
- •7.1.2.3 Leprosy
- •7.1.3 Spirochetal Scleritis
- •7.1.3.1 Syphilis
- •Epidemiology
- •Pathogenesis and Clinical Features
- •Scleritis and Episcleritis
- •Diagnosis
- •Therapy
- •7.1.3.2 Lyme Disease
- •Epidemiology
- •Pathogenesis and Clinical Features
- •Scleritis and Episcleritis
- •Diagnosis
- •7.1.3.3 Treatment
- •7.1.4 Chlamydial Scleritis
- •7.1.5 Actinomycetic Scleritis
- •7.1.5.1 Nocardiosis
- •7.2 Fungal Scleritis
- •7.2.1 Filamentous and Dimorphic Fungal Scleritis
- •7.2.1.1 Pathogenesis
- •7.2.1.2 Organisms
- •7.2.1.3 Management
- •7.2.1.4 Therapy
- •7.2.1.5 Our Experience
- •7.3 Viral Scleritis
- •7.3.1 Herpes Scleritis
- •7.3.1.1 Herpes Zoster Scleritis
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Scleritis
- •Episcleritis
- •Diagnosis
- •Treatment
- •7.3.1.2 Herpes Simplex Scleritis
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Scleritis
- •Episcleritis
- •Diagnosis
- •Therapy
- •Our Experience
- •7.3.2 Mumps Scleritis
- •7.4 Parasitic Scleritis
- •7.4.1 Protozoal Scleritis
- •7.4.1.1 Acanthamoeba
- •7.4.1.2 Toxoplasmosis
- •7.4.2 Helminthic Scleritis
- •7.4.2.1 Toxocariasis
- •7.5 Summary
- •References
- •8.1 Scleral Deposits
- •8.1.1 Scleral Protein Deposition
- •8.1.1.1 Porphyria
- •8.1.1.2 Cystinosis
- •8.1.1.3 Alkaptonuria
- •8.1.1.4 Amyloidosis
- •8.1.2 Scleral Lipid Deposition
- •8.1.2.1 Familial Hypercholesterolemia and Histiocytosis X
- •8.1.2.2 Age-Related Degeneration
- •8.1.3 Scleral Carbohydrate Deposition
- •8.1.3.1 Mucopolysaccharidosis
- •8.1.4 Scleral Mineral Deposition: Calcium
- •8.1.4.1 Hyperparathyroidism
- •8.1.4.2 Other Causes of Hypercalcemia
- •8.1.4.3 Age-Related Degeneration
- •Senile Scleral Hyaline Plaques
- •8.1.5 Scleral Pigment Deposition: Bilirubin
- •8.1.5.1 Jaundice
- •8.2 Scleral Thinning (Blue Sclerae)
- •8.2.1 Scleral Thinning in Inherited or Congenital Diseases
- •8.2.1.1 Marfan’s Syndrome
- •8.2.1.2 Osteogenesis Imperfecta
- •8.2.1.3 Pseudoxanthoma Elasticum
- •8.2.1.4 Ehlers–Danlos Syndrome
- •8.2.1.5 Keratoconus
- •8.2.1.6 Buphthalmos
- •8.2.1.7 Coloboma
- •8.2.1.8 Myopia
- •8.2.2 Scleral Thinning in Acquired Diseases
- •8.2.2.2 Paralimbal Scleromalacia
- •8.3 Scleral Thickening
- •8.3.1 Nanophthalmos
- •8.3.2 Scleropachynsis
- •8.3.3 Phthisis Bulbi
- •8.4 Scleral Tumors
- •8.4.1 Dermoid Choristomas
- •8.4.2 Epithelial Tumors
- •8.4.2.1 Papillomas or Intraepithelial Epitheliomas
- •8.4.2.2 Squamous Cell Carcinoma
- •8.4.3 Dense Connective Tissue Tumors
- •8.4.3.1 Nodular Fasciitis
- •8.4.3.2 Fibroma
- •8.4.3.3 Fibrous Histiocytoma
- •8.4.3.4 Sarcomas
- •8.4.4 Vascular Tumors
- •8.4.4.1 Hemangiomas
- •8.4.4.2 Lymphangiomas
- •8.4.5 Blood Cell Tumors
- •8.4.5.1 Leukemia
- •8.4.5.2 Lymphoma and Lymphosarcoma
- •8.4.6 Nervous Tumors
- •8.4.6.2 Neurilemmoma (Schwannoma)
- •8.4.7 Pigmented Tumors
- •8.4.7.1 Nevus
- •8.4.7.2 Melanocytoma
- •8.4.8 Secondary Tumors
- •8.5 Summary
- •References
- •9.1 Treatment of Episcleritis
- •9.2 Treatment of Scleritis
- •9.2.1 Medical Treatment
- •9.2.1.1 Rheumatoid Arthritis
- •9.2.1.2 Systemic Lupus Erythematosus
- •9.2.1.3 Polyarteritis Nodosa
- •9.2.1.4 Granulomatosis with Polyangiitis (Wegener)
- •9.2.1.5 Relapsing Polychondritis
- •9.2.1.7 Posterior Scleritis
- •9.2.1.8 Infectious Scleritis
- •9.2.2 Ancillary Therapy
- •9.2.3 Drug Management Responsibility
- •9.2.4 Surgical Treatment
- •9.3 Summary
- •References
- •Index
5.2 Specific Considerations of Scleral Tissue Inflammation |
141 |
|
|
Deposition of immune complexes in and around the vessel wall is thought to be an important event in the genesis of vessel damage in systemic vasculitic syndromes often associated with scleritis. DeÞnitive proof of the presence of immune complexes in vessel wall deposits requires the demonstration of speciÞc antigen and antibody. However, common practice in diagnosing systemic vasculitic syndromes (often associated with scleritis) dictates that detection of immunoglobulins and complement components in vessel walls provides evidence of immune complex deposition, even if the relevant antigen is unknown, much less detected. This detection can be done by use of immunoßuorescence or immunoperoxidase techniques (Fig. 3.32). Recognizing the limitations in the interpretation of these Þndings, we therefore also deÞne inßammatory microangiopathy as immunoreactant (immunoglobulin and complement component) deposition in capillaries and postcapillary venules, such as conjunctival, episcleral, and perforating scleral vessels.
5.2.1Pathology of Episcleritis
Light and electron microscopic studies of episcleral tissue in simple and nodular episcleritis cases show chronic, nongranulomatous inßammation with lymphocytes and plasma cells, vascular dilatation, and edema [21, 22]. Some cases in association with connective tissue diseases may reveal the presence of a granulomatous inßammation with epithelioid cells and some multinucleated giant cells, with or without central necrosis, resembling the histopathological picture seen in subcutaneous rheumatoid nodules [23Ð26]. Relatively few cases of episcleritis have been studied histologically, probably because there has been little reason to biopsy episcleral tissue: episcleral inßammation is a benign entity with a tendency to disappear spontaneously over the course of several weeks, and pathological studies are usually noncontributory to the diagnosis or to the treatment.
5.2.2Pathology of Scleritis
5.2.2.1 Noninfectious Scleritis
Light and electron microscopic studies of ocular tissue in patients with noninfectious scleritis may show the same characteristic morphologic changes regardless of whether the scleral inßammation is associated with autoimmune systemic diseases, follows surgical or accidental trauma, or is idiopathic [27Ð29]. InÞltration of the sclera with inßammatory cells may derive from the superÞcial and deep episcleral vessels, the perforating scleral vessels, and the choroidal vessels. All types of scleritis are histologically similar but vary in severity of morphologic changes, necrotizing scleritis having obviously the most destructive lesions.
Because scleral inßammation is always accompanied by episcleral inßammation and often by conjunctival, uveal tract, and corneal inßammation, we describe the morphological changes in sclera, episclera, conjunctiva, uveal tract, and cornea. Occasionally, other ocular structures, including trabecular meshwork, retina, optic nerve, and extraocular muscles, may also be involved in scleritis.
Sclera
Cells
The sclera in necrotizing scleritis reveals a granulomatous inßammatory reaction, the center of which consists of an area of Þbrinoid necrosis surrounded by epithelioid cells, multinucleated giant cells, lymphocytes, plasma cells, and less often neutrophils [27Ð32]. The involved sclera is diffusely thickened. Mast cells and eosinophils can occasionally be seen throughout the granuloma and around vessels. Fibroblasts within the granuloma either are absent or display degenerative changes, including membrane disruption and loss of organelles; however, in the area outside the granuloma they appear to be metabolically active, containing active cell surfaces with peripheral pseudopodia extending into the surrounding matrix, numerous lysosomal granules and mitochondria, and prominent
142 |
5 Pathology in Scleritis |
|
|
Table 5.1 Cellular inÞltrates in scleral granulomas |
|
|
|
Cell |
Productsa |
Macrophage |
Neutral proteases (collagenase, elastase), acid hydrolases, CCs ROIs, IL-1, factor V, |
|
thromboplastin, PDGF, FGF, TGF-§, AAs, PA |
|
|
T lymphocytes |
|
Helper/inducer |
LDCF, IL-2, IL-3, GM-CSF, FGF, TGF-§, angiogenic factors |
Suppressor/cytotoxic |
Suppressor factors |
|
|
Fibroblasts |
Extracellular matrix components, collagenase, proteoglycanase elastase, |
|
glycoproteinase, AAs, GM-CSF, IL-1 |
|
|
B lymphocytes/plasma cells |
Antibodies |
Neutrophils |
Neutral proteases (collagenase, elastase), ROIs, AAs |
LangerhansÕ cells |
IL-1 |
|
|
Mast cells |
Heparin, histamine |
Eosinophils |
Acid hydrolases, neutral proteases (collagenase) |
aROIs reactive oxygen intermediates, IL-1, -2, and -3 interleukins 1, 2, and 3, PDGF platelet-derived growth factor, FGF Þbroblast growth factor, TGF-ß transforming growth factor §, AAs arachidonic acid metabolites, PA plasminogen activator, CC complement components, LDCF lymphocyte-derived chemotactic factor, GM-CSF granulocytemacrophage colony-stimulating factors
rough endoplasmic reticulum and Golgi apparatus (Þbroblastic cells) [27]. Cellular inÞltrates in scleral granulomas secrete a plethora of enzymes and mediators that interact in a complex pattern to orchestrate the development and perpetuation of the inßammatory process (Table 5.1).
The sclera in diffuse and nodular scleritis shows a nongranulomatous inßammatory reaction characterized by inÞltration of mononuclear cells, such as macrophages, lymphocytes, and plasma cells. In some cases, however, especially in the most severe ones, mononuclear cells organize into granulomatous lesions. Mast cells, neutrophils, and eosinophils also may be present.
We biopsied the sclera of 26 of 34 (76%) of our patients with noninfectious necrotizing scleritis. Scleral tissue was obtained in many instances at the time of necrotic tissue removal in those cases requiring scleral grafting for structural support (13 patients) [33]. Scleral tissue was processed for histopathological studies and stained with hematoxylinÐeosin and alkaline Giemsa. HematoxylinÐeosin stains cell nuclei blue and collagen red. Alkaline Giemsa stains mast cell granules metachromatically purple and eosinophil granules red.
The most frequent histopathological Þnding in sclera consisted of a central focus of Þbrinoid necrosis surrounded by granulomatous inßammation
Fig. 5.3 Scleral biopsy, patient with necrotizing scleritis. Note the granuloma formation with perivasculitis, neutrophil margination in the venule, and the multinucleated giant cell at the edge of the venule
with epithelioid cells, lymphocytes, and plasma cells (Fig. 5.3) (Table 5.2). A moderate number of multinucleated giant cells containing a row of nuclei arranged along the periphery were also present in some cases (Fig. 5.4). In addition, scattered numbers of neutrophils, mast cells (Fig. 5.5), and eosinophils (Fig. 5.6) were dispersed throughout the inßamed tissue and around vessels. Areas outside the granuloma were inÞltrated by macrophages, lymphocytes, and plasma cells (Fig. 5.7).
Thirteen of 112 (12%) of our patients with noninfectious diffuse and nodular scleritis
5.2 Specific Considerations of Scleral Tissue Inflammation |
143 |
|
|
Table 5.2 Analysis of hystopathology of scleritis
|
Necrotizing (%)a |
Nonnecrotizing |
||
Cell subset |
(n = 26) |
(%)a (n = 13) |
||
Macrophage |
26 |
(100) |
13 |
(100) |
|
|
|
|
|
Lymphocyte |
26 |
(100) |
13 |
(100) |
Plasma cell |
26 |
(100) |
13 |
(100) |
|
|
|
|
|
Epithelioid cell |
22 |
(85) |
3 |
(23) |
Multinucleated |
7 |
(27) |
0 |
|
giant cells |
|
|
|
|
|
|
|
|
|
Neutrophil |
13 |
(50) |
3 |
(23) |
Mast cell |
8 |
(31) |
4 |
(31) |
Eosinophil |
9 |
(35) |
2 |
(15) |
|
|
|
|
|
a%, Percentage of patients with necrotizing and nonnecrotizing scleritis with the different cell subsets
Fig. 5.4 Same patient as in Fig. 5.3: different Þeld of the specimen, showing many multinucleated giant cells (MagniÞcation, ×160; hematoxylinÐeosin stain)
Fig. 5.6 Scleral biopsy. Note the striking presence of eosinophils in this specimen (MagniÞcation, ×60; hematoxylinÐeosin stain)
Fig. 5.7 Granuloma in a scleral biopsy from a patient with necrotizing scleritis. Note the granuloma and the presence of histiocytes, lymphocytes, and plasma cells in areas surrounding the granuloma
Fig. 5.5 Scleral biopsy of a specimen from a patient with scleritis. Note the large number of purple-stained cells in the specimen, the mast cells (MagniÞcation, ×40; alkaline Giemsa stain)
underwent scleral biopsy. All patients had had recurrent attacks of active scleritis for at least 6 months. Examination under light microscopy
revealed in all cases mononuclear cell inÞltration, including macrophages and lymphocytes without Þbrinoid necrosis (Table 5.2). In addition, some specimens showed the presence of epithelioid cells characteristic of granulomatous inßammation; none had multinucleated giant cells. Neutrophils and mast cells were scattered in the tissues of some patients.
IdentiÞcation of cellular subsets and surface glycoproteins in necrotizing scleritis was accomplished with the use of the immunoperoxidase technique, using monoclonal antibodies directed against T lymphocytes (CD3), T helper/inducer lymphocytes (CD4), T cytotoxic/suppressor lymphocytes (CD8), neutrophils (CD16), B lymphocytes (CD22), macrophages (CD14), HLA-DR
144 |
5 Pathology in Scleritis |
|
|
Table 5.3 Mononuclear cell subset antibody panel in immunoperoxidase studies
Antibody |
SpeciÞcity |
|
|
|
|
Anti-CD3 |
T lymphocytes |
|
|
||
|
|
||||
Anti-CD8 |
T suppressor/cytotoxic lymphocytes |
||||
Anti-CD4 |
T helper/inducer lymphocytes |
|
|||
|
|
|
|
||
Anti-CD16 |
Neutrophils |
|
|
||
Anti-CD22 |
B lymphocytes |
|
|
||
Anti-CD14 |
Macrophages |
|
|
||
|
|
||||
Anti-HLA-DR |
HLA-DR (class II histocompatibility |
||||
|
antigen) |
|
|
|
|
Anti-CD1 |
LangerhansÕ cells |
|
|
||
|
|
|
|||
Table 5.4 Cell subsets in scleritisa |
|
|
|||
|
|
|
|
||
|
|
Scleral specimen |
|
||
|
|
|
|
||
Cell subset |
|
Normal (n = 4) |
Scleritis (n = 9) |
||
Macrophages (CD14) |
0.00 |
± 0.00b |
43.50 |
± 10.91b |
|
T lymphocytes (CD3) |
0.17 |
± 0.10b |
145.70 ± 59.46b |
||
T helper/inducer |
|
0.10 |
± 0.10b |
192.37 ± 41.24b |
|
lymphocytes (CD4) |
|
|
|
|
|
T cytotoxic/suppressor |
0.19 |
± 0.13b |
89.96 |
± 38.15b |
|
lymphocytes (CD8) |
|
|
|
|
|
|
|
|
|
|
|
Neutrophils (CD16) |
0.00 |
± 0.00 |
44.56 |
± 34.86 |
|
B lymphocytes (CD22) |
0.20 |
± 0.12 |
58.56 |
± 39.59 |
|
|
|
|
|
||
HLA-DR glycoproteins |
1.46 |
± 0.22b |
210.00 ± 59.46b |
||
(HLA-DR) |
|
|
|
|
|
LangerhansÕ cells |
|
0.00 |
± 0.00 |
6.96 |
± 5.47 |
(CD1) |
|
|
|
|
|
T helper/T suppressor |
1.09 |
± 0.06b |
8.20 |
± 4.47b |
|
ratio |
|
|
|
|
|
aMean cell count/mm,2 ± standard error of the mean bSigniÞcant values, using StudentÕs t test (P < 0.05)
glycoproteins(anti-HLA-DR)(BectonDickinson, Inc., Mountain View, CA), and LangerhansÕ cells (CD1) (Ortho Pharmaceuticals Corp., Raritan, NJ) (Table 5.3). Details of tissue processing and staining have been previously published [28]. A comparison between nine scleral specimens from patients with necrotizing scleritis and four scleral specimens from normal eyes (New England Eye Bank, Boston, MA), revealed a predominance of macrophages (CD14) and T lymphocytes (CD3) in scleral tissue (Table 5.4). Although both T helper/inducer lymphocytes (CD4) and T suppressor/cytotoxic (CD8) lymphocytes were increased, a high T helper/T suppressor ratio revealed a predominance of the former. Neutrophils (CD16), Langerhans cells (CD1),
and B lymphocytes (CD22) were present in scleritis but their numbers were not signiÞcantly increased when compared with normal tissue. HLA-DR glycoproteins (anti-HLA-DR), present constitutively in macrophages, and after inßammatory stimuli in scleral Þbroblasts and endothelial cells, were markedly increased. These Þndings show the participation of macrophages and T lymphocytes, particularly T helper lymphocytes, in scleritis, and support the idea that macrophages and Þbroblasts activate T lymphocytes, which in turn may participate in granuloma formation. Damaged endothelial cells also may play a role as antigen-presenting cells. The T helper/T suppressor imbalance may contribute to the perpetuation of the highly inßammatory nature of the lesion. In addition to the predominant macrophages and T helper lymphocytes, neutrophils, B lymphocytes, and Langerhans cells may be present.
Extracellular Matrix
Collagen degradation may take place by two mechanisms, one (intracellular) involving acid proteases of macrophages, and the other (extracellular) involving neutral proteases (collagenase and elastase) of Þbroblasts and macrophages [34].
In intracellular digestion of collagen, the collagen Þbrils undergo phagocytosis into phagolysosomes (acid pH) of macrophages, where lysosomal acid proteases lead to tissue breakdown. In extracellular digestion, the collagen Þbrils appear swollen and unraveled in areas of scleral stroma (neutral pH) as a result of the release of neutral proteases by Þbroblasts and macrophages into the connective tissue matrix. Both intracellular and extracellular mechanisms of collagen degradation may occur simultaneously, distant from the granuloma, suggesting that collagen degradation may precede granuloma formation in scleral inßammation [35].
Degradation of collagen may be almost total in the center of the granuloma. Fibril fragments may be found in close apposition to the Þbroblast plasma membrane or enclosed in invaginations of the Þbroblast plasma membrane or vacuole membranes within the cytoplasm (intracellular mechanism). Derangements of collagen Þbril
5.2 Specific Considerations of Scleral Tissue Inflammation |
145 |
|
|
|
|
Table 5.5 Antibody panel used in immunoßuorescence studies |
|
|
|
|
|
Antibody |
Working dilution |
Vendora |
Rabbit anti-collagen I |
1:20 |
Biodesign International |
Goat anti-collagen II |
1:20 |
Southern Biotechnology Associates |
|
|
|
Goat anti-collagen III |
1:20 |
Southern Biotechnology Associates |
Goat anti-collagen IV |
1:100 |
Biodesign International |
|
|
|
Goat anti-collagen V |
1:20 |
Southern Biotechnology Associates |
Mouse anti-collagen VI |
1:20 |
Gift of E. Engvall (La Jolla Cancer |
|
|
Research Foundation, La Jolla, CA) |
|
|
|
Mouse anti-collagen VII |
1:20 |
Chemicon International |
Rabbit anti-collagen IX |
1:20 |
Assay Biotech |
Rabbit anti-collagen XII |
1:20 |
Assay Biotech |
|
|
|
Rabbit anti-collagen XIII |
1:20 |
Assay Biotech |
Rabbit anti-collagen XIV |
1:20 |
Assay Biotech |
Rabbit anti-collagen XVII |
1:20 |
GenWay Biotech, Inc., San Diego, CA |
|
|
|
Mouse anti-heparan sulfate proteoglycan |
Undiluted |
Chemicon International |
Mouse anti-dermatan sulfate proteoglycan |
1:50 |
Seikagaku Kogyo |
|
|
|
Mouse anti-hyaluronic acidb |
Undiluted |
Serotec |
Mouse anti-chondroitin sulfate |
1:50 |
Serotec |
Rabbit anti-Þbronectin |
1:10 |
Organon Teknika-Cappel ScientiÞc |
|
|
|
Rabbit anti-vitronectin |
1:10 |
Chemicon International |
Mouse anti-laminin (200 kDa) |
1:10 |
Chemicon International |
aBiodesign International (Kennebunkport, ME); Southern Biotechnology Associates (Birmingham, AL); Chemicon International (Temecula, CA); Assay Biotech (Sunnyvale, CA); Seikagaku Kogyo (Tokyo, Japan); Organon TeknikaCappel ScientiÞc (West Chester, PA)
bMouse antibody believed to recognize hyaluronic acid (Serotec, Kidlington, England)
structure, such as Þbril swelling and unraveling, irregular contour, and increased interÞbrillar distance, may also be seen without close apposition to active Þbroblasts (extracellular mechanism) [35]. In areas distal to the inßammatory focus, collagen appears normal by light microscopy; however, intracellular or extracellular resorptive changes in the absence of inßammatory cells can be seen by electron microscopy [35, 36].
Electron microscopy studies with cuprolinic blue staining show that proteoglycans are reduced or absent in areas of active scleral inßammation before the collagen Þbrils undergo resorptive changes; these results suggest that proteoglycan degradation precedes collagen degradation [37]. Our own studies on immunolocalization of extracellular matrix components in two diseased scleral specimens as compared with Þve normal scleral specimens show similar Þndings. An indirect immunoßuorescence technique was performed in anterior, equatorial, and posterior areas, using monoclonal antibodies against the
proteoglycans heparan sulfate, dermatan sulfate, hyaluronic acid, and chondroitin sulfate, collagen types I, II, III, IV, V, VI, VII, IX, XII, XIII, XIV, XVII, and the glycoproteins Þbronectin, vitronectin, and laminin (Table 5.5).
1.Proteoglycans. The most abundant proteoglycans in normal sclera were dermatan sulfate and chondroitin sulfate; hyaluronic acid and heparan sulfate also were present, although in small amounts. Dermatan sulfate in necrotizing scleritis was frankly decreased when compared to normal sclera. A negative background with scattered areas of mild patchy positivity in diseased sclera contrasted with an intense striped pattern in normal sclera. (Figs. 5.8 and 5.9). Chondroitin sulfate in necrotizing scleritis also showed a marked reduction in amount of staining, unlike normal sclera, which showed a generalized speckled pattern of intense positivity (Figs. 5.10 and 5.11). Because the presence of heparan sulfate and hyaluronic acid was detected in small amounts
146 |
5 Pathology in Scleritis |
|
|
Fig. 5.8 Immunoßuorescence microscopy: specimen is from a patient with scleritis. The antibody is antidermatan sulfate antibody. Note (in comparison to Fig. 5.9) the dramatic reduction in the presence of dermatan sulfate in the scleritis specimen
Fig. 5.9 Immunoßuorescence microscopy: biopsy of normal sclera. Antibody is antidermatan sulfate antibody. Note the large amount of bright apple-green ßuorescence, indicating rather large amounts of dermatan sulfate in normal sclera (MagniÞcation, ×100)
Fig. 5.10 Immunoßuorescence microscopy: scleral biopsy from a patient with scleritis. Note (particularly in relationship to Fig. 5.11) the relative lack of bright staining, except around the vessels, indicating a relative paucity of chondroitin sulfate in this scleral specimen (MagniÞcation, ×40)
Fig. 5.11 Immunoßuroescence microscopy: normal sclera. Antibody is anti-chondroitin sulfate antibody. Note the relative abundance of bright apple-green Þbrils, indicating a relatively large amount of chondroitin sulfate in normal sclera (MagniÞcation, ×40)
in normal sclera, comparison of these proteoglycans between normal and diseased sclera did not show obvious differences.
2.Collagens. The most abundant types of collagen in normal extravascular sclera were collagens type I and III collagens; type V and type VI also were present. Type II, VII, IX, XII, XIII, XIV, and XVII were not identiÞed. Collagen type IV also was absent except for its dramatic presence in the vessels. Comparison of staining of collagen types I, III, V, and VI between normal and necrotizing scleritis specimens did not show differences in
intensity or pattern. Collagen types I and III showed intense homogeneous Þbrillar staining; these two collagen types impart tensile strength (type I) and resilience (type III) to the scleral ÒskeletonÓ [38]. Collagen type V showed mild, delicate, patchy, granular staining, particularly associated with the edges of the collagen bundles; this pattern leads us to suspect that collagen V forms a Þne network that maintains the structural integrity of the main Þbril core (types I and III). Collagen type VI showed an intense, Þne, regional, granular staining; this pattern also leads us to
